SPHK1 is a novel target of metformin in ovarian cancer

Peter C. Hart, Tatsuyuki Chiyoda, Xiaojing Liu, Melanie Weigert, Marion Curtis, Chun Yi Chiang, Rachel Loth, Ricardo Lastra, Stephanie M. McGregor, Jason W. Locasale, Ernst Lengyel, Iris L. Romero

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motility. Similarly, sphingosine kinases (SPHK), which catalyze the formation of S1P and thus regulate the sphingolipid rheostat, have been reported to promote tumor growth in a variety of cancers. The findings reported here show that exogenous S1P or overexpression of SPHK1 increased proliferation, migration, invasion, and stem-like phenotypes in ovarian cancer cell lines. Likewise, overexpression of SPHK1 markedly enhanced tumor growth in a xenograft model of ovarian cancer, which was associated with elevation of key markers of proliferation and stemness. The diabetes drug, metformin, has been shown to have anticancer effects. Here, we found that ovarian cancer patients taking metformin had significantly reduced serum S1P levels, a finding that was recapitulated when ovarian cancer cells were treated with metformin and analyzed by lipidomics. These findings suggested that in cancer the sphingolipid rheostat may be a novel metabolic target of metformin. In support of this, metformin blocked hypoxia-induced SPHK1, which was associated with inhibited nuclear translocation and transcriptional activity of hypoxiainducible factors (HIF1a and HIF2a). Further, ovarian cancer cells with high SPHK1 were found to be highly sensitive to the cytotoxic effects ofmetformin, whereas ovarian cancer cells with low SPHK1 were resistant. Together, the findings reported here show that hypoxia-induced SPHK1 expression and downstream S1P signaling promote ovarian cancer progression and that tumors with high expression of SPHK1 or S1P levels might have increased sensitivity to the cytotoxic effects of metformin. Implications: Metformin targets sphingolipid metabolism through inhibiting SPHK1, thereby impeding ovarian cancer cell migration, proliferation, and self-renewal.

Original languageEnglish (US)
Pages (from-to)870-881
Number of pages12
JournalMolecular Cancer Research
Volume17
Issue number4
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Metformin
Ovarian Neoplasms
Sphingolipids
Neoplasms
Cell Movement
Cell Proliferation
Sphingosine
Growth
Heterografts
sphingosine 1-phosphate
Phospholipids
Phenotype
Cell Line

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Hart, P. C., Chiyoda, T., Liu, X., Weigert, M., Curtis, M., Chiang, C. Y., ... Romero, I. L. (2019). SPHK1 is a novel target of metformin in ovarian cancer. Molecular Cancer Research, 17(4), 870-881. https://doi.org/10.1158/1541-7786.MCR-18-0409

SPHK1 is a novel target of metformin in ovarian cancer. / Hart, Peter C.; Chiyoda, Tatsuyuki; Liu, Xiaojing; Weigert, Melanie; Curtis, Marion; Chiang, Chun Yi; Loth, Rachel; Lastra, Ricardo; McGregor, Stephanie M.; Locasale, Jason W.; Lengyel, Ernst; Romero, Iris L.

In: Molecular Cancer Research, Vol. 17, No. 4, 01.01.2019, p. 870-881.

Research output: Contribution to journalArticle

Hart, PC, Chiyoda, T, Liu, X, Weigert, M, Curtis, M, Chiang, CY, Loth, R, Lastra, R, McGregor, SM, Locasale, JW, Lengyel, E & Romero, IL 2019, 'SPHK1 is a novel target of metformin in ovarian cancer', Molecular Cancer Research, vol. 17, no. 4, pp. 870-881. https://doi.org/10.1158/1541-7786.MCR-18-0409
Hart, Peter C. ; Chiyoda, Tatsuyuki ; Liu, Xiaojing ; Weigert, Melanie ; Curtis, Marion ; Chiang, Chun Yi ; Loth, Rachel ; Lastra, Ricardo ; McGregor, Stephanie M. ; Locasale, Jason W. ; Lengyel, Ernst ; Romero, Iris L. / SPHK1 is a novel target of metformin in ovarian cancer. In: Molecular Cancer Research. 2019 ; Vol. 17, No. 4. pp. 870-881.
@article{809b4466e38744c0a52072eb9c323f53,
title = "SPHK1 is a novel target of metformin in ovarian cancer",
abstract = "The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motility. Similarly, sphingosine kinases (SPHK), which catalyze the formation of S1P and thus regulate the sphingolipid rheostat, have been reported to promote tumor growth in a variety of cancers. The findings reported here show that exogenous S1P or overexpression of SPHK1 increased proliferation, migration, invasion, and stem-like phenotypes in ovarian cancer cell lines. Likewise, overexpression of SPHK1 markedly enhanced tumor growth in a xenograft model of ovarian cancer, which was associated with elevation of key markers of proliferation and stemness. The diabetes drug, metformin, has been shown to have anticancer effects. Here, we found that ovarian cancer patients taking metformin had significantly reduced serum S1P levels, a finding that was recapitulated when ovarian cancer cells were treated with metformin and analyzed by lipidomics. These findings suggested that in cancer the sphingolipid rheostat may be a novel metabolic target of metformin. In support of this, metformin blocked hypoxia-induced SPHK1, which was associated with inhibited nuclear translocation and transcriptional activity of hypoxiainducible factors (HIF1a and HIF2a). Further, ovarian cancer cells with high SPHK1 were found to be highly sensitive to the cytotoxic effects ofmetformin, whereas ovarian cancer cells with low SPHK1 were resistant. Together, the findings reported here show that hypoxia-induced SPHK1 expression and downstream S1P signaling promote ovarian cancer progression and that tumors with high expression of SPHK1 or S1P levels might have increased sensitivity to the cytotoxic effects of metformin. Implications: Metformin targets sphingolipid metabolism through inhibiting SPHK1, thereby impeding ovarian cancer cell migration, proliferation, and self-renewal.",
author = "Hart, {Peter C.} and Tatsuyuki Chiyoda and Xiaojing Liu and Melanie Weigert and Marion Curtis and Chiang, {Chun Yi} and Rachel Loth and Ricardo Lastra and McGregor, {Stephanie M.} and Locasale, {Jason W.} and Ernst Lengyel and Romero, {Iris L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1541-7786.MCR-18-0409",
language = "English (US)",
volume = "17",
pages = "870--881",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - SPHK1 is a novel target of metformin in ovarian cancer

AU - Hart, Peter C.

AU - Chiyoda, Tatsuyuki

AU - Liu, Xiaojing

AU - Weigert, Melanie

AU - Curtis, Marion

AU - Chiang, Chun Yi

AU - Loth, Rachel

AU - Lastra, Ricardo

AU - McGregor, Stephanie M.

AU - Locasale, Jason W.

AU - Lengyel, Ernst

AU - Romero, Iris L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motility. Similarly, sphingosine kinases (SPHK), which catalyze the formation of S1P and thus regulate the sphingolipid rheostat, have been reported to promote tumor growth in a variety of cancers. The findings reported here show that exogenous S1P or overexpression of SPHK1 increased proliferation, migration, invasion, and stem-like phenotypes in ovarian cancer cell lines. Likewise, overexpression of SPHK1 markedly enhanced tumor growth in a xenograft model of ovarian cancer, which was associated with elevation of key markers of proliferation and stemness. The diabetes drug, metformin, has been shown to have anticancer effects. Here, we found that ovarian cancer patients taking metformin had significantly reduced serum S1P levels, a finding that was recapitulated when ovarian cancer cells were treated with metformin and analyzed by lipidomics. These findings suggested that in cancer the sphingolipid rheostat may be a novel metabolic target of metformin. In support of this, metformin blocked hypoxia-induced SPHK1, which was associated with inhibited nuclear translocation and transcriptional activity of hypoxiainducible factors (HIF1a and HIF2a). Further, ovarian cancer cells with high SPHK1 were found to be highly sensitive to the cytotoxic effects ofmetformin, whereas ovarian cancer cells with low SPHK1 were resistant. Together, the findings reported here show that hypoxia-induced SPHK1 expression and downstream S1P signaling promote ovarian cancer progression and that tumors with high expression of SPHK1 or S1P levels might have increased sensitivity to the cytotoxic effects of metformin. Implications: Metformin targets sphingolipid metabolism through inhibiting SPHK1, thereby impeding ovarian cancer cell migration, proliferation, and self-renewal.

AB - The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motility. Similarly, sphingosine kinases (SPHK), which catalyze the formation of S1P and thus regulate the sphingolipid rheostat, have been reported to promote tumor growth in a variety of cancers. The findings reported here show that exogenous S1P or overexpression of SPHK1 increased proliferation, migration, invasion, and stem-like phenotypes in ovarian cancer cell lines. Likewise, overexpression of SPHK1 markedly enhanced tumor growth in a xenograft model of ovarian cancer, which was associated with elevation of key markers of proliferation and stemness. The diabetes drug, metformin, has been shown to have anticancer effects. Here, we found that ovarian cancer patients taking metformin had significantly reduced serum S1P levels, a finding that was recapitulated when ovarian cancer cells were treated with metformin and analyzed by lipidomics. These findings suggested that in cancer the sphingolipid rheostat may be a novel metabolic target of metformin. In support of this, metformin blocked hypoxia-induced SPHK1, which was associated with inhibited nuclear translocation and transcriptional activity of hypoxiainducible factors (HIF1a and HIF2a). Further, ovarian cancer cells with high SPHK1 were found to be highly sensitive to the cytotoxic effects ofmetformin, whereas ovarian cancer cells with low SPHK1 were resistant. Together, the findings reported here show that hypoxia-induced SPHK1 expression and downstream S1P signaling promote ovarian cancer progression and that tumors with high expression of SPHK1 or S1P levels might have increased sensitivity to the cytotoxic effects of metformin. Implications: Metformin targets sphingolipid metabolism through inhibiting SPHK1, thereby impeding ovarian cancer cell migration, proliferation, and self-renewal.

UR - http://www.scopus.com/inward/record.url?scp=85064037689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064037689&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-18-0409

DO - 10.1158/1541-7786.MCR-18-0409

M3 - Article

C2 - 30655321

AN - SCOPUS:85064037689

VL - 17

SP - 870

EP - 881

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -